BRAF and melanoma: Thus, the combination therapy mixtures consisting of RAF and MEK specific blockers (e.g., trametinib (U.S. Food and Drug Administration (FDA)-approved MEKi) and dabrafenib (FDA-approved BRAFi)) have emerged as the standard therapy for melanoma patients harboring hotspot BRAF-V600E mutations [8,21].